Table 1.
Characteristics of HIV-1 genotypic resistance test records included in this study.
| Variable | All N = 3133 (100.00%) |
No HIVDR N = 398 (12.70%) |
HIVDR N = 2735 (87.30%) |
|---|---|---|---|
| Sex | |||
| Male | 1126 (35.94%) | 130 (11.55%) | 996 (88.45%) |
| Female | 1982 (63.26%) | 266 (13.42%) | 1716 (86.58%) |
| Unknown | 25 (0.80%) | 2 (8.00%) | 23 (92.00%) |
| Age in years, median (IQR) | 39 (30–46) | 36 (22–43) | 39 (32–46) |
| 18–29 | 750 (23.94%) | 156 (20.80%) | 594 (79.20%) |
| 30–59 | 2284 (72.90%) | 237 (10.38%) | 2047 (89.62%) |
| ≥60 | 99 (3.16%) | 5 (5.05%) | 94 (94.95%) |
| Collection year | |||
| 2018 | 597 (19.06%) | 75 (12.56%) | 522 (87.44%) |
| 2019 | 675 (21.54%) | 78 (11.56%) | 597 (88.44%) |
| 2020 | 763 (24.35%) | 115 (15.07%) | 648 (84.93%) |
| 2021 | 666 (21.26%) | 72 (10.81%) | 594 (89.19%) |
| 2022 a | 432 (13.79%) | 58 (13.43%) | 374 (86.57%) |
| ARV drug regimen | |||
| LPV/r or ATV/r -based | 2830 (90.33%) | 362 (12.79%) | 2468 (87.21%) |
| DRV/r-based b | 30 (0.96%) | 1 (3.33%) | 29 (96.67%) |
| DRV/r-based with RAL | 9 (0.29%) | 0 (0.00%) | 9 (100%) |
| DRV/r-based with DTG | 10 (0.32%) | 1 (10.00%) | 9 (90.00%) |
| RAL-based c | 5 (0.16%) | 1 (20.00%) | 4 (80.00%) |
| DTG-based c | 36 (1.15%) | 7 (19.44%) | 29 (80.56%) |
| NNRTI-based d | 36 (1.15%) | 5 (13.89%) | 31 (86.11%) |
| Unknown | 177 (5.65%) | 21 (11.86%) | 156 (88.14%) |
| HIV VL in log10 copies/mL, median (IQR) e | 4.71 (4.10–5.28) | 4.99 (4.33–5.45) | 4.66 (4.07–5.25) |
| Healthcare facility type | |||
| Outpatients | 2950 (94.16%) | 373 (12.64%) | 2577 (87.36%) |
| Inpatients | 183 (5.84%) | 25 (13.66%) | 158 (86.34%) |
| Level of urbanization f | |||
| Rural subdistricts | 451 (14.40%) | 44 (9.76%) | 407 (90.24%) |
| Peri-urban subdistricts | 480 (15.32%) | 55 (11.46%) | 425 (88.54%) |
| Urban subdistricts | 2202 (70.28%) | 299 (13.58%) | 1903 (86.42%) |
ARV, antiretroviral; ATV/r, ritonavir-boosted atazanavir; copies/mL, copies/millilitre; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; EFV, efavirenz; HIVDR, human immunodeficiency virus drug resistance; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; RAL, raltegravir; VL, viral load. a Data only include period from 1 January 2022 to 30 June 2022. b Etravirine included in 4 regimens containing ritonavir-boosted darunavir. c Regimen did not include a protease inhibitor. d Etravirine included in 1 NNRTI-based regimen. e Most recent HIV VL missing for 104 records. f Categories obtained from integrated development plans and annual reports for individual subdistricts in KwaZulu-Natal.